Heron Therapeutics, Inc. (HRTX)
0.3228
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
0.3181
0.00 (0.00%)
After-Hours: 20:00
Heron Therapeutics Enterprise Value : 167.90M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 167.90M |
| August 21, 2026 | 167.03M |
| August 20, 2026 | 165.28M |
| August 19, 2026 | 166.40M |
| August 18, 2026 | 163.75M |
| August 17, 2026 | 167.37M |
| August 14, 2026 | 170.53M |
| August 13, 2026 | 170.10M |
| August 12, 2026 | 171.33M |
| August 11, 2026 | 168.09M |
| August 10, 2026 | 170.21M |
| August 07, 2026 | 199.73M |
| August 06, 2026 | 201.28M |
| August 05, 2026 | 202.38M |
| August 04, 2026 | 203.65M |
| August 03, 2026 | 203.63M |
| July 31, 2026 | 200.75M |
| July 30, 2026 | 200.98M |
| July 29, 2026 | 200.24M |
| July 28, 2026 | 198.80M |
| July 27, 2026 | 193.74M |
| July 24, 2026 | 193.10M |
| July 23, 2026 | 193.70M |
| July 22, 2026 | 195.33M |
| July 21, 2026 | 197.15M |
| Date | Value |
|---|---|
| July 20, 2026 | 197.76M |
| July 17, 2026 | 195.92M |
| July 16, 2026 | 196.92M |
| July 15, 2026 | 189.91M |
| July 14, 2026 | 188.19M |
| July 13, 2026 | 185.73M |
| July 10, 2026 | 185.25M |
| July 09, 2026 | 187.92M |
| July 08, 2026 | 191.14M |
| July 07, 2026 | 187.39M |
| July 06, 2026 | 188.95M |
| July 02, 2026 | 189.80M |
| July 01, 2026 | 187.15M |
| June 30, 2026 | 187.60M |
| June 29, 2026 | 180.02M |
| June 26, 2026 | 178.99M |
| June 25, 2026 | 175.22M |
| June 24, 2026 | 179.61M |
| June 23, 2026 | 176.84M |
| June 22, 2026 | 178.72M |
| June 18, 2026 | 176.63M |
| June 17, 2026 | 170.94M |
| June 16, 2026 | 169.94M |
| June 15, 2026 | 174.10M |
| June 12, 2026 | 173.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Praxis Precision Medicines, Inc. | 9.517B |
| Tonix Pharmaceuticals Holding Corp. | 34.10M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.489M |
| Revenue (Quarterly) | 37.67M |
| Total Expenses (Quarterly) | 43.16M |
| EPS Diluted (Quarterly) | -0.0288 |
| Gross Profit Margin (Quarterly) | 69.28% |
| Profit Margin (Quarterly) | -14.57% |
| Earnings Yield | -58.86% |
| Normalized Earnings Yield | -44.05 |